Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

The CRISPR pioneer Feng Zhang is launching yet another ambitious gene-editing startup, backed by approximately $200 million from some of biotech's biggest investors. The Cambridge, Massachusetts ...

“Building on the success of CASGEVY ... with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.

“Building on the success of CASGEVY&CloseCurlyQuote ... with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, ...